TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling

Abstract

PurposeTRIM29 overexpression has been reported in several human malignancies and showed correlation with cancer cell malignancy. The aim of the current study is to examine its clinical significance and biological roles in human bladder cancer tissues and cell lines.Materials and MethodsA total of 102 cases of bladder cancer tissues were examined for TRIM29 expression by immunohistochemistry. siRNA and plasmid transfection were performed in 5637 and BIU-87 cell lines. Cell Counting Kit-8, flow cytometry, western blot, and real-time polymerase chain reaction were performed to examine its biological roles and mechanism in bladder cancer cells.ResultsWe found that TRIM29 overexpression showed correlation with invading depth (p=0.0087). Knockdown of TRIM29 expression in bladder cancer cell line 5637 inhibited cell growth rate and cell cycle transition while its overexpression in BIU-87 cells accelerated cell proliferation and cell cycle progression. TRIM29 overexpression also inhibited cell apoptosis induced by cisplatin. In addition, we demonstrated that TRIM29 depletion decreased while its overexpression led to upregulated expression of cyclin D1, cyclin E, and Bcl-2. We also showed that TRIM29 knockdown inhibited protein kinase C (PKC) and nuclear factor κB (NF-κB) signaling while its overexpression stimulated the PKC and NF-κB pathways. BAY 11-7082 (NF-κB inhibitor) partly attenuated the effect of TRIM29 on expression of cyclin and Bcl-2. Treatment with PKC inhibitor staurosporine resulted in ameliorated TRIM29 induced activation of NF-κB.ConclusionThe current study demonstrated that TRIM29 upregulates cyclin and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC–NF-κB signaling pathways.

Effects of MicroRNA-499 On the Inflammatory Damage of Endothelial Cells During Coronary Artery Disease Via the Targeting of PDCD4 Through the NF-Κβ/TNF-α Signaling Pathway

“…The tumor suppressor PDCD4 is often down-regulated in several malignancies, and its protein expression could be modulated by miR-21, indicating that PDCD4 down-regulation is a reliable biomarker for early-stage squamous cell esophageal neoplasia [29] In addition, compared to the normal group, NF-κB and TNF-α expression and the apoptosis rates were all increased. The NF-κB/TNF-α signaling pathway has been reported to promote cancer cell growth, angiogenesis, invasion, and eventually metastasis in many human tumors [30, 31]. As an important transcription factor, NF-κB is responsible for a variety of biological processes that participate in the transcription of proinflammatory genes, thus mediating cellular inflammatory responses, including the elevated expression of chemokines and cytokines [32].…”

MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C

“…Therefore, more accurate indices for clinical staging, treatment and prognosis of bladder cancer are urgently required (4,5). The occurrence and development of bladder cancer is the result of the combined action of several types of pathways, which involve various mRNA and microRNA (miRNA or miR) molecules (6,7). The activation of the vascular endothelial growth factor C (VEGF-C) signaling pathway is closely associated with bladder cancer (8).…”

ATDC promotes the growth and invasion of hepatocellular carcinoma cells by modulating GSK‐3β/Wnt/β‐catenin signalling

“…33,43,44 In addition to its ability to inhibit tumour suppressors, ATDC also exerts its oncogenic role through inducing the activation of oncogenic signalling pathways, such as nuclear factor-κB (NF-κB) and Akt. 28,45,46 Notably, the regulatory effect of Nevertheless, our study revealed that ATDC contributes to HCC progression associated with the regulation of GSK-3β/Wnt/β-catenin signalling.…”

“…ATDC is reported to promote tumour progression by inhibiting tumour suppressors including phosphatase and tensin homolog deleted on chromosome ten (PTEN) and p53 . In addition to its ability to inhibit tumour suppressors, ATDC also exerts its oncogenic role through inducing the activation of oncogenic signalling pathways, such as nuclear factor‐κB (NF‐κB) and Akt . Notably, the regulatory effect of ATDC on the activation of Wnt/β‐catenin signalling during tumour progression has been highlighted in recent years.…”